Jane Street’s Day One Biopharmaceuticals DAWN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-475,436
| Closed | -$10.2M | – | 11815 |
|
|
2026
Q1 | $10.2M | Sell |
475,436
-369,718
| -44% | -$5.21M | ﹤0.01% | 2515 |
|
|
2025
Q4 | $7.88M | Buy |
845,154
+565,810
| +203% | +$4.73M | ﹤0.01% | 2620 |
|
|
2025
Q3 | $1.97M | Buy |
+279,344
| New | +$1.92M | ﹤0.01% | 4969 |
|
|
2025
Q2 | – | Sell |
-30,910
| Closed | -$245K | – | 9817 |
|
|
2025
Q1 | $245K | Buy |
+30,910
| New | +$333K | ﹤0.01% | 8138 |
|
|
2024
Q4 | – | Sell |
-69,757
| Closed | -$972K | – | 9583 |
|
|
2024
Q3 | $972K | Sell |
69,757
-110,027
| -61% | -$1.57M | ﹤0.01% | 5950 |
|
|
2024
Q2 | $2.48M | Buy |
179,784
+123,010
| +217% | +$1.8M | ﹤0.01% | 4141 |
|
|
2024
Q1 | $938K | Buy |
56,774
+17,471
| +44% | +$261K | ﹤0.01% | 5538 |
|
|
2023
Q4 | $574K | Buy |
+39,303
| New | +$476K | ﹤0.01% | 6532 |
|
|
2023
Q3 | – | Sell |
-36,611
| Closed | -$478K | – | 8753 |
|
|
2023
Q2 | $437K | Sell |
36,611
-61,984
| -63% | -$810K | ﹤0.01% | 6520 |
|
|
2023
Q1 | $1.32M | Buy |
+98,595
| New | +$1.93M | ﹤0.01% | 4516 |
|
Other funds holding DAWN
Jane Street's DAWN Position: Q2 2026 in Review
Jane Street sold out of Day One Biopharmaceuticals (DAWN) in Q2 2026, closing a stake of 475,436 shares — an estimated $10.2M sold.
Jane Street first reported a position in DAWN in Q1 2023 and held it in 10 quarters. The position peaked at $10.2M in Q1 2026. 1 fund tracked by Wall St. Rank holds DAWN as of Q2 2026.
- Jane Street reported no remaining Day One Biopharmaceuticals position as of Q2 2026 after selling out during the quarter.
- Jane Street sold 475,436 Day One Biopharmaceuticals shares in Q2 2026, an estimated $10.2M.
- Jane Street first reported a position in Day One Biopharmaceuticals in Q1 2023 and held it in 10 quarters.
- Jane Street's Day One Biopharmaceuticals position peaked at $10.2M in Q1 2026.
- 1 fund tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q2 2026.
Based on Jane Street's 13F filing for Q2 2026, filed 14 Aug 2026.